Dorrapharma is engaged in R&D, manufacture and market of intermediates, APIs (Active Pharmaceutical Ingredients) and formulations. We own the core technology advantage in the professional area of bromination, enzyme/metal-catalyzed, nitration and hydrogenation, and obtain multiple core patents for invention. We stick to raising the value both for the company and customers, and strive for creating more valuable product for the health of the life. We devote ourselves completely to the technology innovation and brand build and make every effort to foster the core competence for the company with the company mission of a leading integrated operator with its core competitive advantage in global pharmaceutical market.

Dorra always adheres to the independent R&D-powered business policy, assured with production, market and quality. Located in Taizhou industrial park with 5000 square meters R&D center dedicates to the research of new compound innovation and the development of the safe, environmental friendly and highly efficient synthesis process. The manufacturing sites are approved by China GMP, ISO9001, EU authorities, FDA, Japan PMDA，etc. The therapeutic areas cover anti-infection, cardiovascular, digestive system, antithrombotics and etc. The products and services have been mainly supplied to Europe, North America, South Asia and other countries and areas by enjoying a high prestige and good reputation.

We are consecutive to concern about the public and repay the society with strong responsibility and social mission along with the healthy and steady development of our company. With the mission of "creating more valuable products for life and health", we are committed to fulfill our social responsibility as an excellent enterprise.